Biosimilars geautoriseerd door het EMA (op datum)

Update 28 augustus 2026

De informatie in de tabel is gebaseerd op beschikbare informatie van het EMA (inclusief CHMP-meeting highlights van juli 2026).

Biosimilar	Datum CHMP advies	Indicatie	Registratiehouder	Autorisatie*
Pegfilgrastim (Cavoley®)	jul-26	Reduction of neutropenia in adults	CuraTeQ Biologics s.r.o	Pending EC decision
Denosumab (Denosumab Ascend®)	jun-26	Prevention of skeletal related events and treatment of giant cell tumour of bone	Ascend GmbH	Pending EC decision
Pegfilgrastim (Nylaspeg®)	jun-26	Reduction of neutropoenia in adults	Qilu Pharma Spain S.L.	Pending EC decision
Ranibizumab (Vislyfa®)	mei-26	The treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema (DME) proliferative diabetic retinopathy (PDR), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO, visual impairment due to choroidal neovascularisation (CNV)	Lupin Europe GmbH	jul-26
Ranibizumab (Rexatilux®)	apr-26	Treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema (DME), proliferative diabetic retinopathy (PDR), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to choroidal neovascularisation (CNV)	Intas Third Party Sales 2005 S.L.	jun-26
Insulin lispro (Bysumlog®)	feb-26	Treatment of diabetes mellitus.	Gan & Lee Pharmaceuticals Europe GmbH	mei-26
Insulin aspart (Dazparda®)	feb-26	Treatment of diabetes mellitus from 1 year of age	Gan & Lee Pharmaceuticals Europe GmbH	apr-26
Etanercept (Fubelv®)	feb-26	Treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (ankylosing spondylitis, non-radiographic axial spondyloarthritis), plaque psoriasis, paediatric plaque psoriasis	Biosimilar Collaborations Ireland Limited	apr-26
Pertuzumab (Poherdy®)	feb-26	Treatment of breast cancer in adults.	Organon N.V.	apr-26
Tocilizumab (Tuyory®)	feb-26	Treatment of rheumatoid arthritis (RA), coronavirus disease 2019 (COVID-19), systemic juvenile idiopathic arthritis (sJIA), polyarticular juvenile idiopathic arthritis (pJIA), CAR-T cell-induced severe or life-threatening cytokine release syndrome (CRS), and giant cell arteritis (GCA)	Gedeon Richter Plc.	apr-26
Teriparatide (Zandoriah®)	feb-26	Treatment of osteoporosis	Cinnagen Co Unipessoal Lda.	apr-26
Golimumab (Gotenfia®)	dec-25	Treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis and ulcerative colitis	STADA Arzneimittel AG	feb-26

Biosimilar	Datum CHMP advies	Indicatie	Registratiehouder	Autorisatie*
Ranibizumab (Ranluspec®)	dec-25	Treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment and other retinopathies.	Lupin Europe GmbH	feb-26
Denosumab (Osqay®)	nov-25	Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, treatment of bone loss associated with hormone ablation in men with prostate cancer and treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients	Theramex Ireland Limited	jan-26
Insulin glargine (Ondibta®)	nov-25	Treatment of diabetes mellitus	Gan & Lee Pharmaceuticals Europe GmbH	jan-26
Denosumab (Zvogra®)	sep-25	Prevention of skeletal related events in adults and treatment of adults and skeletally mature adolescents with giant cell tumour of bone	Stada Arzneimittel AG	nov-25
Denosumab (Xbonzy®)	sep-25	Prevention of skeletal related events in adults and treatment of adults and skeletally mature adolescents with giant cell tumour of bone	Reddy Holding GmbH	nov-25
Denosumab (Ponlimsi®)	sep-25	Treatment of osteoporosis and bone loss	Teva GmbH	nov-25
Denosumab (Kefdensis®)	sep-25	Treatment of osteoporosis and bone loss	STADA Arzneimittel AG	nov-25
Denosumab (Denosumab Intas®)	sep-25	Treatment of osteoporosis and bone loss	Intas Third Party Sales 2005 S.L.	nov-25
Denosumab (Degevma®)	sep-25	Prevention of skeletal related events in adults and treatment of adults and skeletally mature adolescents with giant cell tumour of bone	Teva GmbH	nov-25
Denosumab (Acvybra®)	sep-25	Treatment of osteoporosis and bone loss	Reddy Holding GmbH	nov-25
Ustekinumab (Usgena®)	sep-25	Treatment of Crohn's disease, plaque psoriasis and paediatric plaque psoriasis, psoriatic arthritis, and ulcerative colitis.	Stada Arzneimittel AG	nov-25
Golimumab (Gobivaz®)	sep-25	Treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis and ulcerative colitis	Advanz Pharma Limited	nov-25
Ustekinumab (Usrenty®)	jul-25	Treatment of Crohn's disease, treatment of plaque psoriasis and paediatric plaque psoriasis, and psoriatic arthritis	Biosimilar Collaborations Ireland Limited	sept-25
Aflibercept (Eyluxvi®)	jul-25	Treatment of age-related macular degeneration (AMD) and visual impairment	Biolitec pharma Limited Zweigniederlassung Jena	sep-25
Denosumab (Bilprevda®)	jul-25	Prevention of skeletal related events in adults with advanced malignancies involving bone	Henlius Europe GmbH	sep-25
Denosumab (Bildyos®)	jul-25	Treatment of osteoporosis and bone loss	Henlius Europe GmbH	sep-25
Pegfilgrastim (Vivlipeg®)	jun-25	To reduce the duration of neutropenia and the incidence of febrile neutropenia after cytotoxic chemotherapy	Biosimilar Collaborations Ireland Limited	aug-25
Ustekinumab (Usymro®)	jun-25	Treatment of plaque psoriasis arthritis psoriatic and Crohn's Disease	Elc Group s.r.o	aug-25
Aflibercept (Vgenfli®)	jun-25	Treatment of age-related macular degeneration (AMD) and visual impairment	Zaklady Farmaceutyczne Polpharma S.A	aug-25

Biosimilar	Datum CHMP advies	Indicatie	Registratiehouder	Autorisatie*
Aflibercept (Mynzepli®)	jun-25	Treatment of age-related macular degeneration (AMD) and visual impairment	Advanz Pharma Limited	aug-25
Aflibercept (Eiyzey®)	jun-25	Treatment of age-related macular degeneration (AMD) and visual impairment	Zaklady Farmaceutyczne Polpharma S.A	aug-25
Aflibercept (Afiveg®)	jun-25	Treatment of age-related macular degeneration (AMD) and visual impairment	Stada Arzneimittel AG	aug-25
Denosumab (Rolcya®)	mei-25	Treatment of osteoporosis and bone loss	Sandoz GmbH	jul-25
Denosumab (Conexxence®)	mei-25	Treatment of osteoporosis and bone loss	Fresenius Kabi Deutschland GmbH	jul-25
Denosumab (Bomyntra®)	mei-25	Prevention of skeletal related events in adults with advanced malignancies involving bone	Fresenius Kabi Deutschland GmbH	jul-25
Denosumab (Zadenvi®)	apr-25	Treatment of osteoporosis and bone loss	Zentiva k.s.	jun-25
Denosumab (Yaxwer®)	apr-25	Prevention of skeletal related events in adults with advanced malignancies, treatment of adults and skeletally mature adolescents with giant cell tumour of bone	Gedeon Richter Plc.	jun-25
Denosumab (Vevzuo®)	apr-25	Prevention of skeletal related events in adults with advanced malignancies, treatment of adults and skeletally mature adolescents with giant cell tumour of bone	Biosimilar Collaborations Ireland Limited	jun-25
Denosumab (Junod®)	apr-25	Treatment of osteoporosis and bone loss	Gedeon Richter Plc.	jun-25
Denosumab (Izamby®)	apr-25	Treatment of osteoporosis and bone loss	Mabxience Research S.L.	jun-25
Denosumab (Enwylma®)	apr-25	Prevention of skeletal related events in adults with advanced malignancies, treatment of adults and skeletally mature adolescents with giant cell tumour of bone	Zentiva k.s.	jun-25
Denosumab (Evfraxy®)	apr-25	Treatment of osteoporosis and bone loss	Biosimilar Collaborations Ireland Limited	aug-25
Denosumab (Denbrayce®)	apr-25	Prevention of skeletal related events in adults with advanced malignancies, treatment of adults and skeletally mature adolescents with giant cell tumour of bone	Mabxience Research S.L.	jun-25
Trastuzumab (Dazublys®)	apr-25	Treatment of metastatic and early breast cancer	CuraTeQ Biologics s.r.o.	jun-25
Denosumab (Osvyrti®)	mrt-25	Treatment of osteoporosis and bone loss	Accord Healthcare S.L.U.	mei-25
Ustekinumab (Qoyvolma®)	mrt-25	Treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis	Celltrion Healthcare Hungary Kft.	jun-25
Denosumab (Jubereq®)	mrt-25	Prevention of skeletal related events in adults with advanced malignancies involving bone	Accord Healthcare S.L.U.	mei-25
Aflibercept (Pavblu®)	jan-25	Treatment of age-related macular degeneration (AMD) and visual impairment	Amgen Technology (Ireland) Unlimited Company	apr-25
Pegfilgrastim (Dyrupeg®)	jan-25	Treatment of neutropenia	CuraTeQ Biologics s.r.o.	mrt-25
Filgrastim (Zefylti®)	dec-24	Reduction in the duration of neutropenia and the incidence of febrile neutropenia	CuraTeQ Biologics s.r.o.	feb-25

Biosimilar	Datum CHMP advies	Indicatie	Registratiehouder	Autorisatie*
Ustekinumab (Yesintek®)	dec-24	Treatment of plaque psoriasis, paediatric plaque psoriasis, psoriatic arthritis, Crohn's disease	Biosimilar Collaborations Ireland Limited	feb-25
Denosumab (Stoboclo®)	dec-24	Treatment of osteoporosis and bone loss	Hungary Kft.	feb-25
Denosumab (Osenvelt®)	dec-24	Prevention of skeletal related events with advanced malignancies	Celltrion Healthcare Hungary Kft.	feb-25
Aflibercept (Eydenzelt®)	dec-24	Treatment of age-related macular degeneration (AMD) and visual impairment	Celltrion Healthcare Hungary Kft.	feb-25
Tocilizumab (Avtozma®)	dec-24	Treatment of rheumatoid arthritis	Celltrion Healthcare Hungary Kft.	feb-25
Aflibercept (Baiama®)	nov-24	Treatment of age-related macular degeneration (AMD) and visual impairment	Formycon AG	jan-25
Aflibercept (Ahzantive®)	nov-24	Treatment of age-related macular degeneration (AMD) and visual impairment	Klinge Biopharma GmbH	jan-25
Denosumab (Xbryk®)	nov-24	Prevention of skeletal related events with advanced malignancies and treatment of giant cell tumour of bone	Samsung Bioepis NL B.V.	feb-25
Denosumab (Obodence®)	nov-24	Treatment of osteoporosis and bone loss	Samsung Bioepis NL B.V.	feb-25
Ustekinumab (Imuldosa®)	okt-24	Treatment of plaque psoriasis, paediatric plaque psoriasis, psoriatic arthritis (PsA), Crohn's disease	Accord Healthcare S.L.U.	dec-24
Aflibercept (Opuviz®)	sep-24	Treatment of age-related macular degeneration (AMD) and visual impairment	Samsung Bioepis NL B.V.	dec-24
Aflibercept (Afqlir®)	sep-24	Treatment of age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO), due to diabetic macular oedema (DME) and due to myopic choroidal neovascularisation (myopic CNV) or central RVO)	Sandoz GmbH	nov-24
Rituximab (Ituxredi®)	jul-24	Treatment of Non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukaemia (CLL) and Rheumatoid arthritis	Reddy Holding GmbH	sep-24
Trastuzumab (Tuznue®)	jul-24	Indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) and HER2 positive early breast cancer (EBC)	Prestige Biopharma Belgium	sep-24
Ranibizumab (Ranibizumab Midas®)	jul-24	Treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema (DME), proliferative diabetic retinopathy (PDR), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) and visual impairment due to choroidal neovascularisation (CNV)	MIDAS Pharma GmbH	sep-24
Ustekinumab (Otulfi®)	jul-24	Treatment of Crohn's disease, Plaque psoriasis, Paediatric plaque psoriasis and Psoriatic arthritis (PsA)	Fresenius Kabi Deutschland GmbH	sep-24
Ustekinumab (Fymskina®)	jul-24	Treatment of Crohn's disease, Ulcerative colitis, Plaque psoriasis, Paediatric plaque psoriasis and Psoriatic arthritis (PsA)	Formycon AG	sep-24
Ustekinumab (Steqeyma®)	jun-24	Treatment of adult patients with moderately to severely active Crohn's disease, plaque psoriasis, paediatric plaque psoriasis and Psoriatic arthritis (PsA)	Celltrion Healthcare Hungary Kft.	aug-24

Biosimilar	Datum CHMP advies	Indicatie	Registratiehouder	Autorisatie*
Bevacizumab (Avzivi®)	mei-24	Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer. First line treatment of patients with advanced and/or metastatic renal cell cancer	FGK Representative Service GmbH	jul-24
Tocilizumab (Tociluzumab STADA; v/h Tofidence®)	apr-24	Treatment of rheumatoid arthritis (RA), coronavirus disease 2019 (COVID-19), polyarticular juvenile idiopathic arthritis (pJIA), and systemic juvenile idiopathic arthritis (sJIA)	Biogen Netherlands B.V.	jun-24
Ustekinumab (Wezenla®)	apr-24	Treatment of moderate to severe plaque psoriasis in adults, children and adolescents, active psoriatic arthritis in adults and Crohn's Disease	Amgen Technology (Ireland) Unlimited Company	jun-24
Denosumab (Jubbonti®)	mrt-24	Treatment of osteoporosis	Sandoz GmbH	mei-24
Denosumab (Wyost®)	mrt-24	Prevention of skeletal related events with advanced malignancies	Sandoz GmbH	mei-24
Omalizumab (Omlyclo®)	mrt-24	Treatment of asthma	Celltrion Healthcare Hungary Kft.	mei-24
Ustekinumab (Pyzchiva®)	feb-24	Treatment of Crohn's disease, Ulcerative colitis, Plaque psoriasis, Paediatric plaque psoriasis and Psoriatic arthritis (PsA)	Samsung Bioepis NL B.V.	apr-24
Ranibizumab (Rimmyrah®)	nov-23	Treatment of neovascular age-related macular degeneration (AMD)	QILU PHARMA SPAIN S.L.	jan-24
Ustekinumab (Uzpruvo®)	nov-23	Treatment of plaque psoriasis, arthritis psoriatic and Crohn's Disease	STADA Arzneimittel AG	jan-24
Trastuzumab (Herwenda®)	sep-23	Treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)	Sandoz GmbH	nov-23
Aflibercept (Yesafili®)	jul-23	Treatment of age-related macular degeneration (AMD) and visual impairment	Viatris Limited	sep-23
Natalizumab (Tyruko®)	jul-23	Therapy for active relapsing remitting multiple sclerosis (RRMS)	Sandoz GmbH	sep-23
Tocilizumab (Tyenne®)	jul-23	Rheumatoid Arthritis Cytokine Release Syndrome Juvenile Rheumatoid Arthritis COVID-19 virus infection Giant Cell Arteritis	Fresenius Kabi Deutschland GmbH	sep-23
Eculizumab (Epysqli®)	mrt-23	Treatment of paroxysmal nocturnal haemoglobinuria in adults and children	Samsung Bioepis NL B.V.	mei-23
Eculizumab (Bekemv®)	feb-23	Treatment of paroxysmal nocturnal haemoglobinuria in adults and children	Amgen Technology (Ireland) Unlimited Company	apr-23
Teriparatide (Kauliv®)	nov-22	Treatment of osteoporosis	Strides Pharma Cyprus	jan-23
Ranibizumab (Ximluci®)	sep-22	Treatment of neovascular age-related macular degeneration	STADA Arzneimittel AG	nov-22
Ranibizumab (Ranivisio®)	jun-22	Treatment of neovascular (wet) age-related macular degeneration, visual impairment due to macular oedema or choroidal neovascularisation, and proliferative diabetic retinopathy	Midas Pharma GmbH	aug-22

Biosimilar	Datum CHMP advies	Indicatie	Registratiehouder	Autorisatie*
Bevacizumab (Vegzelma®)	jun-22	Treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix	Celltrion Healthcare Hungary Kft	aug-22
Insulin aspart (Truvelog Mix 30®)	feb-22	Treatment of diabetes mellitus	sanofi-aventis groupe	apr-22
Pegfilgrastim (Stimufend®)	jan-22	Reduction of the duration of neutropenia and the incidence of febrile neutropenia after cytotoxic chemotherapy	Fresenius Kabi Deutschland GmbH	mrt-22
Teriparatide (Sondelbay®)	jan-22	Treatment of osteoporosis	Accord Healthcare S.L.U.	mrt-22
Adalimumab (Hukyndra®)	sep-21	Treatment of inflammatory auto-immune disorders	STADA Arzneimittel AG	nov-21
Adalimumab (Libmyris®)	sep-21	Treatment of inflammatory auto-immune disorders	STADA Arzneimittel AG	nov-21
Ranibizumab (Byooviz®)	jun-21	Wet Macular Degeneration, Macular Edema, Diabetic Retinopathy, Degenerative Myopia	Samsung Bioepis NL B.V.	aug-21
Bevacizumab (Abevmy®)	feb-21	Colorectal Neoplasms; Breast Neoplasms; Non-Small-Cell Lung Carcinoma; Renal Cell Carcinoma; Uterine Cervical Neoplasms	Mylan IRE Healthcare Limited	apr-21
Bevacizumab (Alymsys®)	jan-21	Colorectal Neoplasms; Breast Neoplasms; Non-Small-Cell Lung Carcinoma; Renal Cell Carcinoma; Uterine Cervical Neoplasms	Mabxience Research SL	mrt-21
Bevacizumab (Oyavas®)	jan-21	Colorectal Neoplasms; Breast Neoplasms; Non-Small-Cell Lung Carcinoma; Renal Cell Carcinoma; Uterine Cervical Neoplasms	STADA Arzneimittel AG	mrt-21
Adalimumab (Yuflyma®)	dec-20	Rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn's disease, paediatric Crohn's disease, ulcerative colitis, uveitis and paediatric uveitis	Celltrion Healthcare Hungary Kft.	feb-21
Insulin aspart (Kirsty®; v/h Kixelle®)	dec-20	Treatment of diabetes mellitus	Mylan IRE Healthcare Limited	feb-21
Bevacizumab (Onbevzi®)	nov-20	Colorectal Neoplasms; Breast Neoplasms; Non-Small-Cell Lung Carcinoma; Renal Cell Carcinoma; Uterine Cervical Neoplasms	Samsung Bioepis NL B.V.	jan-21
Pegfilgrastim (Nyvepria®)	sep-20	Neutropenia	Pfizer Europe MA EEIG	nov-20
Bevacizumab (Equidacent®)	jul-20	Colorectal Neoplasms; Breast Neoplasms; Non-Small-Cell Lung Carcinoma; Renal Cell Carcinoma; Uterine Cervical Neoplasms	Centus Biotherapeutics Europe Limited	sep-20 teruggetrokken nov-21
Teriparatide (Livogiva®)	jun-20	Treatment of osteoporosis	Theramex Ireland Limited	aug-20
Bevacizumab (Aybintio®)	jun-20	Colorectal Neoplasms; Breast Neoplasms; Non-Small-Cell Lung Carcinoma; Renal Cell Carcinoma; Uterine Cervical Neoplasms	Samsung Bioepis NL B.V.	aug-20
Trastuzumab (Zercepac®)	mei-20	Treatment of breast and gastric cancer	Accord Healthcare S.L.U.	jul-20
Insulin aspart (Insulin aspart Sanofi®)	apr-20	Treatment of diabetes mellitus	sanofi-aventis groupe	jun-20

Biosimilar	Datum CHMP advies	Indicatie	Registratiehouder	Autorisatie*
Etanercept (Nepexto®)	mrt-20	The treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (ankylosing spondylitis, non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis.	Mylan IRE Healthcare Limited	mei-20
Rituximab (Ruxience®)	jan-20	The treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and Pemphigus vulgaris.	Pfizer Europe MA EEIG	apr-20
Adalimumab (Amsparity®)	dec-19	Rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn's disease, paediatric Crohn's disease, ulcerative colitis, uveitis and paediatric uveitis	Pfizer Europe MA EEIG	feb-20
Pegfilgrastim (Cegfila®)	okt-19	Neutropenia	Mundipharma Biologics S.L.	dec-19
Pegfilgrastim (Grasustek®)	apr-19	Neutropenia	Juta Pharma GmbH	apr-19
Adalimumab (Idacio®)	jan-19	Rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn's disease, paediatric Crohn's disease, ulcerative colitis, uveitis and paediatric uveitis	Fresenius Kabi	apr-19
Bevacizumab (Zirabev®)	dec-18	Colorectal Neoplasms; Breast Neoplasms; Non-Small-Cell Lung Carcinoma; Renal Cell Carcinoma; Uterine Cervical Neoplasms	Pfizer	feb-19
Trastuzumab (Ogivri®)	okt-18	Metastatic breast cancer, early breast cancer and metastatic gastric cancer	Mylan	dec-18
Pegfilgrastim (Fulphila®)	sep-18	Neutropenia	Mylan	nov-18
Pegfilgrastim (Pelmeg®)	sep-18	Neutropenia	Cinfa Biotech S.L.	nov-18
Pegfilgrastim (Ziextenzo®)	sep-18	Neutropenia	Sandoz	nov-18
Pegfilgrastim (Pelgraz®)	jul-18	Neutropenia	Accord Healthcare	sep-18
Pegfilgrastim (Udenyca®)	jul-18	Neutropenia	ERA Consulting	sep-18
Adalimumab (Hulio®)	jul-18	Rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn's disease, paediatric Crohn's disease, ulcerative colitis, uveitis and paediatric uveitis	Mylan	sep-18
Adalimumab (Hefiya®)	mei-18	Juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, uveitis and paediatric uveitis	Sandoz	jul-18
Adalimumab (Hyrimoz®)	mei-18	Rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn's disease, paediatric Crohn's disease, ulcerative colitis, uveitis and paediatric uveitis	Sandoz	jul-18

Biosimilar	Datum CHMP advies	Indicatie	Registratiehouder	Autorisatie*
Trastuzumab (Trazimera®)	mei-18	Metastatic breast cancer, early breast cancer and metastatic gastric cancer	Pfizer	jul-18
Infliximab (Zessly®)	mrt-18	Rheumatoid arthritis, adult and paediatric Crohn's disease, ulcerative colitis, paediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis	Sandoz	mei-18
Trastuzumab (Kanjinti®)	mrt-18	Metastatic breast cancer, early breast cancer and metastatic gastric cancer	Amgen	mei-18
Insulin glargine (Semglee®)	jan-18	Diabetes Mellitus	Mylan	mrt-18
Trastuzumab (Herzuma®)	dec-17	Metastatic breast cancer, early breast cancer and metastatic gastric cancer	Celltrion	feb-18
Bevacizumab (Mvasi®)	nov-17	Fallopian tube neoplasms, Non-Small-Cell Lung Carcinoma, ovarian neoplasms, Renal Cell Carcinoma, Peritoneal Neoplasms, Breast Neoplasms	Amgen	jan-18
Trastuzumab (Ontruzant®)	sep-17	Metastatic breast cancer, early breast cancer and metastatic gastric cancer	Samsung Bioepis	nov-17
Adalimumab (Imraldi®)	jun-17	Rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn's disease, paediatric Crohn's disease, ulcerative colitis and uveitis	Samsung Bioepis	aug-17
Insulin Lispro (Insulin lispro Sanofi®)	mei-17	Diabetes mellitus	Sanofi	jul-17
Rituximab (Blitzima®)	mei-17	Non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, granulomatosis with polyangiitis and microscopic polyangiitis.	Celltrion	jul-17
Rituximab (Ritemvia®)	mei-17	Non-Hodgkin's lymphoma, granulomatosis with polyangiitis and microscopic polyangiitis.	Celltrion	jul-17
Etanercept (Erelzi®)	apr-17	Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis, paediatric plaque psoriasis.	Sandoz	jun-17
Rituximab (Rixathon®)	apr-17	Non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis	Sandoz	jun-17
Rituximab (Riximyo®)	apr-17	Non-Hodgkin's lymphoma, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis	Sandoz	jun-17
Adalimumab (Amgevita®)	jan-17	Rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn's disease, paediatric Crohn's disease, ulcerative colitis and uveitis	Amgen	mrt-17
Rituximab (Truxima®)	dec-16	Non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis	Celltrion	feb-17
Teriparatide (Movymia®)	nov-16	Osteoporosis	STADA Arzneimittel	jan-17

Biosimilar	Datum CHMP advies	Indicatie	Registratiehouder	Autorisatie*
Teriparatide (Terrosa®)	nov-16	Osteoporosis	Gedeon Richter	jan-17
Enoxaparin (Inhixa®)	jul-16	Prophylaxis of venous thromboembolic disease, deep vein trombosis, pulmonary embolism, acute coronary syndrome and extra corporeal haemodialysis	Techdow	sep-16
Infliximab (Flixabi®)	mrt-16	Rheumatoid arthritis, adult and paediatric Crohn's disease, ulcerative colitis, paediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis	Samsung Bioepis	mei-16
Etanercept (Benepali®)	nov-15	Rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and plaque psoriasis	Samsung Bioepis	jan-16
Filgrastim (Accofil®)	jul-14	Neutropenia	Accord Healthcare	sep-14
Insulin glargine (Abasaglar®)	jun-14	Diabetes Mellitus	Eli Lilly	sep-14
Follitropin alfa (Bemfola®)	jan-14	Anovulation	Finox	mrt-14
Follitropin alfa (Ovaleap®)	aug-13	Anovulation	Teva	sep-13
Filgrastim (Grastofil®)	jul-13	Neutropenia	Apotex	okt-13
Infliximab (Inflectra®)	jun-13	Rheumatoid arthritis, adult and paediatric Crohn's disease, ulcerative colitis, paediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis	Hospira	sep-13 teruggetrokken mei-26
Infliximab (Remsima®)	jun-13	Rheumatoid arthritis, adult and paediatric Crohn's disease, ulcerative colitis, paediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis	Celltrion	sep-13
Filgrastim (Nivestim®)	mrt-10	Neutropenia, Hematopoietic Stem Cell Transplantation, Cancer	Hospira/Pfizer	jun-10
Filgrastim (Filgrastim Hexal®)	nov-08	Neutropenia, Hematopoietic Stem Cell Transplantation, Cancer	Hexal	feb-09
Filgrastim (Zarzio®)	nov-08	Neutropenia, Hematopoietic Stem Cell Transplantation, Cancer	Sandoz	feb-09
Epoetin alfa (Abseamed®)	okt-08	Anaemia, chronic renal failure, cancer	Medice	aug-07
Filgrastim (Ratiograstim®)	jul-08	Neutropenia, Hematopoietic Stem Cell Transplantation, Cancer	Ratiopharm	sep-08
Filgrastim (Tevagrastim®)	jul-08	Neutropenia, Hematopoietic Stem Cell Transplantation, Cancer	Teva	sep-08
Epoetin zeta (Retacrit®)	okt-07	Anaemia, kidney Failure, chronic blood transfusion, autologous cancer	Hospira	dec-07
Epoetin zeta (Silapo®)	okt-07	Anaemia, kidney Failure, chronic blood transfusion, autologous cancer	Stada	dec-07
Epoetin alfa (Binocrit®)	jun-07	Anaemia, chronic renal failure, cancer	Sandoz	aug-07
Epoetin alfa (Epoetin Alfa Hexal®)	jun-07	Anaemia, chronic renal failure, cancer	Hexal	aug-07
Somatropin (Omnitrope®)	jun-03	Growth hormone deficiency, Prader-Willi syndrome, Turner syndrome, chronic renal insufficiency, small for gestational age	Sandoz	apr-06

* De gecentraliseerde vergunning voor het in de handel brengen is geldig in alle EU-lidstaten en in IJsland, Liechtenstein en Noorwegen (EER-landen). De houder van de vergunning voor het in de handel brengen is niet verplicht het product in alle lidstaten te verkopen. De daadwerkelijke marketing is afhankelijk van veel factoren, zoals prijs, terugbetaling en beschikbaarheid van het product.